Table 2

MSTSQ, ISR, and SF-MPQ endpoints during the full-dose period of the comparative phase (intent-to-treat population)
IFNβ-1a (N = 65) IFNβ-1b (N = 64) p-value
MSTSQ assessments
MSTSQ overall satisfaction score,a mean (SD) 1.51 (0.56) 1.53 (0.63) 0.616
MSTSQ injection system score,a mean (SD) 1.68 (0.41) 1.80 (0.45) 0.156
MSTSQ score for background information,a mean (SD) 2.28 (0.91) 2.28 (0.86) 0.734
Blinded assessment of ISRs
Diameter of injection-site redness, mm, mean (SD) 11.32 (14.88) 11.75 (15.53) 0.986
Patients, n (%), with:
  Injection-site swelling 19 (29.2) 16 (25.0) 0.848
  Injection-site bruising 21 (32.3) 7 (10.9) 0.019
  Injection-site itching 7 (10.8) 6 (9.4) 0.366
SF-MPQ assessments
SF-MPQ VAS pain score,b mm, mean (SD) 2.54 (7.98) 3.24 (8.78) 0.612
Patients pain-free on SF-MPQ VAS,b,cn (%) 17 (26.2) 17 (26.6) 0.852

aOn the MSTSQ, a lower score indicates a more favorable response to treatment. bThe SF-MPQ VAS recorded the maximum amount of pain experienced during the 60 min after injection, from 0 mm (no pain) to 100 mm (worst possible pain). cPain-free was defined as an SF-MPQ VAS score of 0 mm.

IFN, interferon; ISR, injection-site reaction; MSTSQ, Multiple Sclerosis Treatment Satisfaction Questionnaire; SD, standard deviation; SF-MPQ, Short-Form McGill Pain Questionnaire; VAS, visual analog scale.

Singer et al.

Singer et al. BMC Neurology 2012 12:154   doi:10.1186/1471-2377-12-154

Open Data